SF

Stephen J. Forman

Stephen J. Forman, M.D., is an internationally recognized expert in hematologic malignancies and bone marrow transplantation and is a leader in preclinical and clinical cancer research. He is co-editor of Thomas’ Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and health care professionals. Dr. Forman is the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, a position he has held since 1987.

In nearly 40 years at City of Hope, Dr. Forman has been instrumental in advancing the survival rates for patients suffering from cancers of the blood and immune system such as leukemia, lymphoma and myeloma.

As Director of the T Cell Immunotherapy Research Laboratory, his current research is focused on cancer immunotherapy — using the body’s own immune system to attack cancer. Pharmacological enhancement of patients’ immune responses to their cancers is of special interest to Lixte as the enzyme target of its lead clinical compound, LB-100, has been reported recently to be critical to immune function. Much of his current work centers on T cells and their cancer-fighting potential.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Lixte Biotechnology

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer.